GSK de­tails Blenrep’s PhI­II com­bo win as it hopes to stage a turn­around in mul­ti­ple myelo­ma

GSK’s Blenrep in com­bi­na­tion with two oth­er med­i­cines cut the risk of dis­ease pro­gres­sion or death by 59% com­pared to a stan­dard com­bi­na­tion for mul­ti­ple …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER